Browse

You are looking at 1 - 5 of 5 items

Mawson Wang Department of Endocrinology and Diabetes, Blacktown Hospital, Sydney, Australia
Blacktown Clinical School, School of Medicine, Western Sydney University, Sydney, Australia

Search for other papers by Mawson Wang in
Google Scholar
PubMed
Close
,
Benjamin Jonker Department of Neurosurgery, St. Vincent’s Hospital, Sydney, Australia

Search for other papers by Benjamin Jonker in
Google Scholar
PubMed
Close
,
Louise Killen Department of Pathology, St. Vincent’s Hospital, Sydney, Australia

Search for other papers by Louise Killen in
Google Scholar
PubMed
Close
,
Yvonne Bogum NSW Health Pathology East, Prince of Wales Hospital, Sydney, Australia

Search for other papers by Yvonne Bogum in
Google Scholar
PubMed
Close
,
Ann McCormack Department of Endocrinology, St. Vincent’s Hospital, Sydney, Australia
Garvan Institute of Medical Research, Sydney, Australia
St. Vincent’s Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, Australia

Search for other papers by Ann McCormack in
Google Scholar
PubMed
Close
, and
Ramy H Bishay Department of Endocrinology and Diabetes, Blacktown Hospital, Sydney, Australia
Blacktown Clinical School, School of Medicine, Western Sydney University, Sydney, Australia

Search for other papers by Ramy H Bishay in
Google Scholar
PubMed
Close

Summary

Cushing’s disease is a rare disorder characterised by excessive cortisol production as a consequence of a corticotroph pituitary tumour. While the primary treatment is surgical resection, post-operative radiation therapy may be used in cases of ongoing inadequate hormonal control or residual or progressive structural disease. Despite improved outcomes, radiotherapy for pituitary tumours is associated with hypopituitarism, visual deficits and, rarely, secondary malignancies. We describe an unusual case of a 67-year-old female with presumed Cushing’s disease diagnosed at the age of 37, treated with transsphenoidal resection of a pituitary tumour with post-operative external beam radiotherapy (EBRT), ketoconazole for steroidogenesis inhibition, and finally bilateral adrenalectomy for refractory disease. She presented 30 years after her treatment with a witnessed generalised tonic-clonic seizure. Radiological investigations confirmed an extracranial mass infiltrating through the temporal bone and into brain parenchyma. Due to recurrent generalised seizures, the patient was intubated and commenced on dexamethasone and anti-epileptic therapy. Resection of the tumour revealed a high-grade osteoblastic osteosarcoma. Unfortunately, the patient deteriorated in intensive care and suffered a fatal cardiac arrest following a likely aspiration event. We describe the risk factors, prevalence and treatment of radiation-induced osteosarcoma, an exceedingly rare and late complication of pituitary irradiation. To our knowledge, this is the longest reported latency period between pituitary irradiation and the development of an osteosarcoma of the skull.

Learning points:

  • Cushing’s disease is treated with transsphenoidal resection as first-line therapy, with radiotherapy used in cases of incomplete resection, disease recurrence or persistent hypercortisolism.

  • The most common long-term adverse outcome of pituitary tumour irradiation is hypopituitarism occurring in 30–60% of patients at 10 years, and less commonly, vision loss and oculomotor nerve palsies, radiation-induced brain tumours and sarcomas.

  • Currently proposed characteristics of radiation-induced osteosarcomas include: the finding of a different histological type to the primary tumour, has developed within or adjacent to the path of the radiation beam, and a latency period of at least 3 years.

  • Treatment of osteosarcoma of the skull include complete surgical excision, followed by systemic chemotherapy and/or radiotherapy.

  • Overall prognosis in radiation-induced sarcoma of bone is poor.

  • Newer techniques such as stereotactic radiosurgery may reduce the incidence of radiation-induced malignancies.

Open access
Mawson Wang Nepean Blue Mountains Local Health District, Katoomba, New South Wales, Australia

Search for other papers by Mawson Wang in
Google Scholar
PubMed
Close
,
Catherine Cho Nepean Blue Mountains Local Health District, Katoomba, New South Wales, Australia

Search for other papers by Catherine Cho in
Google Scholar
PubMed
Close
,
Callum Gray Nepean Blue Mountains Local Health District, Katoomba, New South Wales, Australia

Search for other papers by Callum Gray in
Google Scholar
PubMed
Close
,
Thora Y Chai Department of Endocrinology, Nepean Blue Mountains Local Health District, Kingswood, New South Wales, Australia
Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

Search for other papers by Thora Y Chai in
Google Scholar
PubMed
Close
,
Ruhaida Daud Nepean Blue Mountains Local Health District, Katoomba, New South Wales, Australia

Search for other papers by Ruhaida Daud in
Google Scholar
PubMed
Close
, and
Matthew Luttrell Department of Endocrinology, Nepean Blue Mountains Local Health District, Kingswood, New South Wales, Australia

Search for other papers by Matthew Luttrell in
Google Scholar
PubMed
Close

Summary

We report the case of a 65-year-old female who presented with symptomatic hypercalcaemia (corrected calcium of 4.57 mmol/L) with confusion, myalgias and abdominal discomfort. She had a concomitant metabolic alkalosis (pH 7.46, HCO3 - 40 mmol/L, pCO2 54.6 mmHg). A history of significant Quick-Eze use (a calcium carbonate based antacid) for abdominal discomfort, for 2 weeks prior to presentation, suggested a diagnosis of milk-alkali syndrome (MAS). Further investigations did not demonstrate malignancy or primary hyperparathyroidism. Following management with i.v. fluid rehydration and a single dose of i.v. bisphosphonate, she developed symptomatic hypocalcaemia requiring oral and parenteral calcium replacement. She was discharged from the hospital with stable biochemistry on follow-up. This case demonstrates the importance of a detailed history in the diagnosis of severe hypercalcaemia, with MAS representing the third most common cause of hypercalcaemia. We discuss its pathophysiology and clinical importance, which can often present with severe hypercalcaemia that can respond precipitously to calcium-lowering therapy.

Learning points:

  • Milk-alkali syndrome is an often unrecognised cause for hypercalcaemia, but is the third most common cause of admission for hypercalcaemia.

  • Calcium ingestion leading to MAS can occur at intakes as low as 1.0–1.5 g per day in those with risk factors.

  • Early recognition of this syndrome can avoid the use of calcium-lowering therapy such as bisphosphonates which can precipitate hypocalcaemia.

Open access
Teresa M Canteros Endocrinology, Metabolism and Nuclear Medicine, Hospital Italinao de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Teresa M Canteros in
Google Scholar
PubMed
Close
,
Valeria De Miguel Endocrinology, Metabolism and Nuclear Medicine, Hospital Italinao de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Valeria De Miguel in
Google Scholar
PubMed
Close
, and
Patricia Fainstein-Day Endocrinology, Metabolism and Nuclear Medicine, Hospital Italinao de Buenos Aires, Buenos Aires, Argentina

Search for other papers by Patricia Fainstein-Day in
Google Scholar
PubMed
Close

Summary

Severe Cushing syndrome (SCS) is considered an emergency that requires immediate treatment to lower serum cortisol levels. Fluconazole may be considered an alternative treatment in Cushing syndrome when ketoconazole is not tolerated or unavailable. We report a 39-year-old woman with a history of partial pancreaticoduodenectomy due to a periampullary neuroendocrine tumor with locoregional extension. Three years after surgery, she developed liver metastases and was started on 120 mg of lanreotide/month, despite which, liver metastases progressed in the following 6 months. The patient showed extreme fatigue, muscle weakness, delirium, moon face, hirsutism and severe proximal weakness. Laboratory tests showed anemia, hyperglycemia and severe hypokalemia. 24-h urinary free cortisol: 2152 nmol/day (reference range (RR): <276), morning serum cortisol 4883.4 nmol/L (RR: 138–690), ACTH 127.3 pmol/L (RR: 2.2–10). She was diagnosed with ectopic ACTH syndrome (EAS). On admission, she presented with acute upper gastrointestinal tract bleeding and hemodynamic instability. Intravenous fluconazole 400 mg/day was started. After 48 h, her mental state improved and morning cortisol decreased by 25%. The dose was titrated to 600 mg/day which resulted in a 55% decrease in cortisol levels in 1 week, but then had to be decreased to 400 mg/day because transaminase levels increased over 3 times the upper normal level. After 18 days of treatment, hemodynamic stability, lower cortisol levels and better overall clinical status enabled successful bilateral adrenalectomy. This case report shows that intravenous fluconazole effectively decreased cortisol levels in SCS due to EAS.

Learning points:

  • Severe Cushing syndrome can be effectively treated with fluconazole to achieve a significant improvement of hypercortisolism prior to bilateral adrenalectomy.

  • Intravenous fluconazole is an alternative treatment when ketoconazole is not tolerated and etomidate is not available.

  • Fluconazole is well tolerated with mild side effects. Hepatotoxicity is usually mild and resolves after drug discontinuation.

Open access
Elise Flynn Austin Health, Heidelberg, Victoria, Australia

Search for other papers by Elise Flynn in
Google Scholar
PubMed
Close
,
Sara Baqar Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Sara Baqar in
Google Scholar
PubMed
Close
,
Dorothy Liu University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Dorothy Liu in
Google Scholar
PubMed
Close
,
Elif I Ekinci Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Elif I Ekinci in
Google Scholar
PubMed
Close
,
Stephen Farrell Austin Health, Heidelberg, Victoria, Australia

Search for other papers by Stephen Farrell in
Google Scholar
PubMed
Close
,
Jeffrey D Zajac Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Jeffrey D Zajac in
Google Scholar
PubMed
Close
,
Mario De Luise Austin Health, Heidelberg, Victoria, Australia

Search for other papers by Mario De Luise in
Google Scholar
PubMed
Close
, and
Ego Seeman Austin Health, Heidelberg, Victoria, Australia
University of Melbourne, Parkville, Victoria, Australia

Search for other papers by Ego Seeman in
Google Scholar
PubMed
Close

Summary

ACTH-secreting phaeochromocytoma (ASP) is a rare cause of ACTH-dependent Cushing’s syndrome (CS). We report the case of a 63-year-old female presenting with CS secondary to an ASP complicated by bowel perforation. This case report highlights ASP as an uncommon but important cause of ectopic ACTH secretion (EAS). There have been 29 cases of ASP, all of which were unilateral and benign, but associated with significant complications. Patients presenting with ASP have the potential for cure with unilateral adrenalectomy. Given this promising prognosis if recognised, ASP should be considered in the diagnostic workup of ACTH-dependent CS. As this case demonstrates, gastrointestinal complications can arise from severe hypercortisolaemia associated with CS. Early medical and surgical intervention is imperative as mortality approaches 50% once bowel perforation occurs.

Learning points

  • Consider phaeochromocytoma in the diagnostic workup of ACTH-dependent CS; screen with plasma metanephrines or urinary catecholamines.

  • Serial screening may be required if ACTH-secreting phaeochromocytoma is suspected, as absolute levels can be misleading.

  • Early catecholamine receptor blockade and adrenal synthesis blockade may avoid the need for rescue bilateral adrenalectomy in ACTH-secreting phaeochromocytoma.

  • Consider early medical or surgical management when gastrointestinal features are present in patients with CS, as bowel perforation due to severe hypercortisolaemia can occur and is associated with significant mortality.

Open access
Arshpreet Kaur Division of Endocrinology Metabolism and Diabetes, University of Louisville, 550 South Jackson Street, ACB A3G11, Louisville, Kentucky, 40202, USA

Search for other papers by Arshpreet Kaur in
Google Scholar
PubMed
Close
and
Stephen J Winters Division of Endocrinology Metabolism and Diabetes, University of Louisville, 550 South Jackson Street, ACB A3G11, Louisville, Kentucky, 40202, USA

Search for other papers by Stephen J Winters in
Google Scholar
PubMed
Close

Summary

Drugs that inhibit the sodium-glucose co-transporter-2 (SGLT2) are an exciting novel, insulin-independent treatment for diabetes that block glucose reabsorption from the proximal tubules of the kidney, leading to increased glucose excretion and lower blood glucose levels. Inhibition of SGLT2 activity also reduces sodium reabsorption, which together with glycosuria produces a mild diuretic effect with the potential for dehydration and hyperkalemia. We report on a 60-year-old man with uncontrolled type 2 diabetes treated with insulin, glimepiride, metformin and canagliflozin, who was admitted with altered mental status after a syncopal episode. He had a 1-week history of ingestion of Tums for heartburn followed by poor appetite and lethargy. Laboratory work-up showed acute kidney injury, diabetic ketoacidosis (DKA), and parathyroid hormone-independent severe hypercalcemia of 17.4 mg/dl. DKA resolved with insulin treatment, and saline hydration led to improvement in hypercalcemia and renal function over 48 h, but was accompanied by a rapid increase in the serum sodium concentration from 129 to 162 mmol/l despite changing fluids to 0.45% saline. Urine studies were consistent with osmotic diuresis. Hypernatremia was slowly corrected with hypotonic fluids, with improvement in his mental status over the next 2 days. This is the first report of hypercalcemia associated with the use of a SLGT2 inhibitor. Although the exact mechanism is unknown, canagliflozin may predispose to hypercalcemia in patients ingesting excessive calcium because of dehydration from osmotic diuresis, with reduced calcium excretion and possible increased intestinal calcium absorption. Saline therapy and osmotic diuresis may lead to hypernatremia from electrolyte-free water loss.

Learning points

  • Canagliflozin, an SGLT2 inhibitor, may cause hypercalcemia in susceptible patients.

  • Although the exact mechanisms are unknown, dehydration from osmotic diuresis and increased intestinal calcium absorption play a role.

  • Close monitoring of serum calcium levels is recommended in patients treated with SGLT2 inhibitors who are elderly, have established hypercalcemia, or take oral calcium supplements.

  • Saline therapy and osmotic diuresis may lead to hypernatremia from electrolyte-free water loss in susceptible patients.

Open access